GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (ASX:RMD) » Definitions » E10

ResMed (ASX:RMD) E10 : A$0.65 (As of Mar. 2024)


View and export this data going back to 1999. Start your Free Trial

What is ResMed E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ResMed's adjusted earnings per share data for the three months ended in Mar. 2024 was A$0.311. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is A$0.65 for the trailing ten years ended in Mar. 2024.

During the past 12 months, ResMed's average E10 Growth Rate was 12.60% per year. During the past 3 years, the average E10 Growth Rate was 14.90% per year. During the past 5 years, the average E10 Growth Rate was 13.80% per year. During the past 10 years, the average E10 Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ResMed was 30.10% per year. The lowest was 10.90% per year. And the median was 18.50% per year.

As of today (2024-06-07), ResMed's current stock price is A$31.95. ResMed's E10 for the quarter that ended in Mar. 2024 was A$0.65. ResMed's Shiller PE Ratio of today is 49.15.

During the past 13 years, the highest Shiller PE Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 48.37.


ResMed E10 Historical Data

The historical data trend for ResMed's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed E10 Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.37 0.38 0.51 0.59

ResMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.59 0.64 0.60 0.65

Competitive Comparison of ResMed's E10

For the Medical Instruments & Supplies subindustry, ResMed's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Shiller PE Ratio falls into.



ResMed E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.311/131.7762*131.7762
=0.311

Current CPI (Mar. 2024) = 131.7762.

ResMed Quarterly Data

per share eps CPI Adj_EPS
201406 0.065 100.560 0.085
201409 0.064 100.428 0.084
201412 0.078 99.070 0.104
201503 0.083 99.621 0.110
201506 0.079 100.684 0.103
201509 0.082 100.392 0.108
201512 0.094 99.792 0.124
201603 0.085 100.470 0.111
201606 0.080 101.688 0.104
201609 0.071 101.861 0.092
201612 0.073 101.863 0.094
201703 0.081 102.862 0.104
201706 0.094 103.349 0.120
201709 0.075 104.136 0.095
201712 0.009 104.011 0.011
201803 0.098 105.290 0.123
201806 0.101 106.317 0.125
201809 0.101 106.507 0.125
201812 0.120 105.998 0.149
201903 0.103 107.251 0.127
201906 0.069 108.070 0.084
201909 0.122 108.329 0.148
201912 0.160 108.420 0.194
202003 0.180 108.902 0.218
202006 0.177 108.767 0.214
202009 0.169 109.815 0.203
202012 0.163 109.897 0.195
202103 -0.070 111.754 -0.083
202106 0.174 114.631 0.200
202109 0.190 115.734 0.216
202112 0.192 117.630 0.215
202203 0.165 121.301 0.179
202206 0.189 125.017 0.199
202209 0.214 125.227 0.225
202212 0.227 125.222 0.239
202303 0.237 127.348 0.245
202306 0.232 128.729 0.237
202309 0.232 129.860 0.235
202312 0.212 129.419 0.216
202403 0.311 131.776 0.311

Add all the adjusted EPS together and divide 10 will get our e10.


ResMed  (ASX:RMD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ResMed's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=31.95/0.65
=49.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of ResMed was 102.35. The lowest was 33.33. And the median was 48.37.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ResMed E10 Related Terms

Thank you for viewing the detailed overview of ResMed's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ASX:RMD) Business Description

Traded in Other Exchanges
Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.